Neuro-Hitech Concludes Phase II Trial in Alzheimer's Patients
Posted on: Tuesday, 18 December 2007, 06:00 CST
Neuro-Hitech has completed the double-blind part of its multi-center, randomized, placebo-controlled Phase II clinical trial of Huperzine A in the treatment of patients with mild to moderate Alzheimer's disease.
The study involves 210 patients with mild to moderate Alzheimer's disease (AD). The trial is comparing the safety, tolerability and efficacy of either 200 or 400 micrograms of Huperzine A administered orally twice a day for 16 weeks versus placebo. The trial will measure the efficacy of Huperzine A on cognitive function, activities of daily living and behavior.
Neuro-Hitech expects top-line results from the double-blind part of the study in the first quarter of 2008. At the end of the double-blind part of the study all patients were invited to receive Huperzine A treatment in an open-label fashion for up to one year.
Gary Shearman, president and CEO of Neuro-Hitech, said: "We are very pleased to announce the achievement of this important milestone and look forward to reporting the top-line results in the near future."
Source: Datamonitor
Related Articles
- Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
- Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
- A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
- Recordati Successfully Completes the Silodosin Double-Blind Phase III Study
- Debiopharm S.A. Presented Results of a Double-Blind Placebo-Controlled Study on First-in-Class Debio-025 in HIV-1-Infected Subjects
- Amazon Biotech Announces a New Double-Blind Drug Trial Using AMZ 0026
- Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial
- Double-Blind, Placebo-Controlled Trial of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- Randomized, Double-Blind, Placebo-Controlled Trial of Fluoxetine Treatment for Elderly Patients With Dysthymic Disorder
 |
 |
User Comments (0)
RSS Feeds